Brendan Smith's questions to Schrodinger Inc (SDGR) leadership • Q3 2024
Question
Brendan Smith of TD Cowen asked about the prioritization of non-oncology programs for collaboration versus internal development and plans for building clinical infrastructure in those areas.
Answer
President of R&D Karen Akinsanya stated that while oncology remains a core focus, the company sees a significant opportunity in non-oncology areas with limited small molecule options. She confirmed that Schrodinger is equipped and plans to advance a select number of non-oncology assets into Phase I studies internally, particularly those with clear, early value inflection points.